Brain tumors are one of the leading causes of cancer deaths, but the current conventional treatments for malignant brain tumors are not satisfactory, resulting in a serious disease burden. Despite recent advances in our understanding of the biology of malignant brain tumors, the malignant degree of primary brain tumors is serious, and the incidence rate of brain metastases is gradually increasing. The prognosis of patients is still poor under the standard treatment, including surgery, radiotherapy and chemotherapy, and most patients are not sensitive to traditional treatment. Moreover, compared with other solid tumors, the malignant characteristics of primary brain tumors and brain metastasis, such as rapid and invasive growth, lead to incomplete surgical resection. Due to the existence of blood-brain barrier, the therapeutic effect of radiotherapy and chemotherapy is limited, which seriously threatens the life of patients. These biological factors represent a major challenge in the development of new therapies.
By exploring the targeted therapy and immunotherapy of malignant brain tumors, it may be beneficial to delay primary tumor recurrence, improve the therapeutic effect of brain metastasis, and reduce the drug resistance of related drugs. Therefore, innovative trials and related mechanistic studies of targeted therapy and immunotherapy are needed to ultimately improve the prognosis of patients with malignant brain tumors.
The aim of this topic is to describe the latest advances in targeted therapy and immunotherapy for primary malignant brain tumors and brain metastases, and to explore emerging research and innovative strategies for their treatments. Topics of interest include, but are not limited to, targeted therapy, immunotherapy, and mechanism research that will improve the understanding and treatment of malignant brain tumors.
• Exploration of subgroups of malignant brain tumors and their biomarkers for which immune checkpoint inhibitors respond to treatment
• Exploration of the feasibility and effectiveness of other immunotherapy approaches (including but not limited to cytokine therapy, vaccine therapy, and viral therapy)
• Research on novel targeted therapy drugs based on gene mutations or molecular markers related to the biological behavior of malignant brain tumors
• Identification of new targeted therapeutic pathways for malignant brain tumors
• Assessment of the safety and feasibility of combination immunotherapy
• Comprehensive treatment strategies of primary malignant brain tumors and brain metastases based on targeted therapy, including but not limited to combination with chemotherapy, electric field and other treatment methods
• Clinical management of patients with primary brain tumors and brain metastases receiving targeted therapy
Please note: This Research Topic will not publish Case Reports and research on pediatric brain tumors is outside the scope. Manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Brain tumors are one of the leading causes of cancer deaths, but the current conventional treatments for malignant brain tumors are not satisfactory, resulting in a serious disease burden. Despite recent advances in our understanding of the biology of malignant brain tumors, the malignant degree of primary brain tumors is serious, and the incidence rate of brain metastases is gradually increasing. The prognosis of patients is still poor under the standard treatment, including surgery, radiotherapy and chemotherapy, and most patients are not sensitive to traditional treatment. Moreover, compared with other solid tumors, the malignant characteristics of primary brain tumors and brain metastasis, such as rapid and invasive growth, lead to incomplete surgical resection. Due to the existence of blood-brain barrier, the therapeutic effect of radiotherapy and chemotherapy is limited, which seriously threatens the life of patients. These biological factors represent a major challenge in the development of new therapies.
By exploring the targeted therapy and immunotherapy of malignant brain tumors, it may be beneficial to delay primary tumor recurrence, improve the therapeutic effect of brain metastasis, and reduce the drug resistance of related drugs. Therefore, innovative trials and related mechanistic studies of targeted therapy and immunotherapy are needed to ultimately improve the prognosis of patients with malignant brain tumors.
The aim of this topic is to describe the latest advances in targeted therapy and immunotherapy for primary malignant brain tumors and brain metastases, and to explore emerging research and innovative strategies for their treatments. Topics of interest include, but are not limited to, targeted therapy, immunotherapy, and mechanism research that will improve the understanding and treatment of malignant brain tumors.
• Exploration of subgroups of malignant brain tumors and their biomarkers for which immune checkpoint inhibitors respond to treatment
• Exploration of the feasibility and effectiveness of other immunotherapy approaches (including but not limited to cytokine therapy, vaccine therapy, and viral therapy)
• Research on novel targeted therapy drugs based on gene mutations or molecular markers related to the biological behavior of malignant brain tumors
• Identification of new targeted therapeutic pathways for malignant brain tumors
• Assessment of the safety and feasibility of combination immunotherapy
• Comprehensive treatment strategies of primary malignant brain tumors and brain metastases based on targeted therapy, including but not limited to combination with chemotherapy, electric field and other treatment methods
• Clinical management of patients with primary brain tumors and brain metastases receiving targeted therapy
Please note: This Research Topic will not publish Case Reports and research on pediatric brain tumors is outside the scope. Manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.